

Notal Vision's ForeseeHome™ AMD Monitor Receives FDA Clearance

28/12/2009

Notal Vision's ForeseeHome™ AMD Monitor has received Section 510 (k) clearance from the U.S. Food and Drug Administration (FDA).

The ForeseeHome™ AMD Monitor is the first device of its kind in the eye care industry that allows patients with the dry form of Age-related Macular Degeneration to monitor themselves in the convenience and comfort of their own home with data transmitted to the patient's eye care physician and the Notal Vision Data Monitoring Center. It is ergonomically designed for patient comfort and ease of use.

Notal Vision plans to introduce the ForeseeHome™ AMD Monitor to the market in Q1 2010, with continued investment in clinical research and product development.
